The DUSP12 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from the HeLa host cell line. This polyclonal knockout model enables loss-of-function studies of the dual-specificity phosphatase DUSP12 within a widely used human cervical adenocarcinoma background. The product is supplied as a heterogeneous pool of edited cells, suitable for functional genomics, signaling pathway dissection, and phenotypic screening without the need for single-cell cloning. The gene disruption is achieved using CRISPR/Cas9 technology, generating a mixed population that reflects the complexity of polyclonal knockout responses.
HeLa cells, originally isolated from a cervical adenocarcinoma, are an immortalized epithelial cell line positive for human papillomavirus type 18 (HPV-18). They are extensively employed in cancer biology, protein expression analyses, and cell cycle investigations due to their robust growth and well-characterized signaling networks. Their HPV-18 status and transformed phenotype make HeLa cells particularly relevant for studying oncogenic signaling and tumor suppressor pathway interactions. This host background provides a physiologically pertinent setting for examining DUSP12 function in processes such as proliferation, stress adaptation, and metabolic control.
DUSP12 belongs to the dual-specificity phosphatase family and catalyzes the dephosphorylation of phosphotyrosine and phosphoserine/threonine residues on target substrates. Key molecular targets include glucokinase (GCK) and mitogen-activated protein kinases such as ERK1/2, JNK, and p38. Through these interactions, DUSP12 acts as a negative regulator of MAPK cascades and metabolic signaling, modulating downstream transcription factors like AP-1. The enzyme is activated by stress signals and transcriptional regulatory inputs, positioning it at the intersection of cell cycle progression and cellular stress responses. Mechanistically, DUSP12 dephosphorylates effector proteins, thereby attenuating signaling flux through pathways that govern proliferation, survival, and metabolic homeostasis.
In the HeLa cell context, disruption of DUSP12 provides a relevant model for probing phosphatase-dependent regulation in a cancer cell background. Since HeLa cells harbor HPV-18 oncogenes that alter cell cycle and apoptosis controls, the DUSP12 knockout allows researchers to dissect how phosphatase activity intersects with viral oncoprotein-driven signaling. This is particularly valuable for investigating the role of DUSP12 in neoplastic growth, as altered phosphatase expression programs can influence cancer cell signaling networks. Furthermore, because DUSP12 also links to metabolic circuitry via GCK, this knockout model supports studies on metabolic dysregulation in tumor cells, an area of increasing importance in oncology.
Typical research applications include phosphatase substrate identification, signal transduction studies, cancer cell signaling research, and drug target validation. Representative experimental approaches include western blotting to assess MAPK phosphorylation status, phosphatase activity assays to quantify DUSP12 catalytic function, co-immunoprecipitation to confirm protein?Cprotein interactions, RT-qPCR for transcriptional profiling, and immunofluorescence for spatial analysis of signaling components. The polyclonal nature of the knockout population facilitates comparative studies with wild-type cells, enabling robust phenotypic analysis. For additional technical information or to discuss specific experimental designs, please contact Ascent Research.
